How long does it take for the side effects of Vepotolizumab/Urova to disappear?

Polatuzumab/Polatuzumab, as an antibody-drug conjugate (ADC), can accurately attack cancer cells, but its cytotoxic carrier MMAE may also affect normal tissues, causing certain side effects. The most common reactions include fatigue, peripheral neuropathy, anemia, neutropenia, diarrhea, nausea, pyrexia, and increased risk of infection. The onset time, duration and recovery speed of these side effects depend on the individual differences of the patient and the treatment cycle.

In clinical practice, most patients will experience mild to moderate adverse reactions within the first to second cycle of treatment. Peripheral neuropathy is a more typical side effect, manifesting as numbness or tingling in the limbs. If it is a mild (grade 1) reaction, it will generally recover gradually within a few weeks to one month; if it reaches a moderate to severe reaction (grade 2 or above), the drug may need to be discontinued or treatment reduced, and the recovery period can be extended to several months. Hematological adverse reactions (such as neutropenia) usually reach a trough within 7 to 14 days after treatment, then improve with the recovery of bone marrow function, and return to normal levels after about 2 to 3 weeks.

Some patients may also experience digestive system reactions, such as nausea or diarrhea. Most of these symptoms are transient and usually disappear within 1 to 2 weeks after stopping the drug or receiving symptomatic treatment. If the patient develops complications such as infection or fever, active anti-infective treatment is required and the next dose must be delayed. It is worth noting that most of the side effects associated with vepotuzumab are reversible, and the key lies in timely detection and intervention.

In general, most of the adverse reactions of vepotuzumab gradually resolve within 1 to 3 months after the end of treatment. By regularly monitoring blood and neurological function, rationally adjusting dosage, and maintaining adequate hydration and nutritional support, the vast majority of patients can safely survive the treatment period.

Reference materials:https://www.drugs.com/polivy.html